Coherus Oncology (CHRS) Operating Expenses (2013 - 2026)
Coherus Oncology (CHRS) posted Operating Expenses of $48.5 million for Q1 2026, down 17.34% sequentially from $58.6 million in Q4 2025, and down 8.62% YoY from $53.0 million in Q1 2025.
Coherus Oncology (CHRS) Operating Expenses (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Operating Expenses for 14 years, with the latest figure at $48.5 million in Q1 2026.
- Quarterly Operating Expenses fell 8.62% year-over-year to $48.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.7 million (up 4.67% YoY) and the FY2025 annual result came in at $223.3 million, down 1.21% from the prior year.
- Operating Expenses retreated to $48.5 million in Q1 2026 per CHRS's latest filing, from $58.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $160.4 million in Q4 2023 and troughed at $48.5 million in Q1 2026.
- A 5-year average of $83.9 million and a median of $70.1 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 65.66% in 2023, then tumbled 66.89% in 2024.
- Over 5 years, Operating Expenses stood at $96.8 million in 2022, then soared by 65.66% to $160.4 million in 2023, then sank by 66.89% to $53.1 million in 2024, then gained by 10.38% to $58.6 million in 2025, then decreased by 17.34% to $48.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $48.5 million, $58.6 million, and $55.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 46.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.64 Mn |
| Mar 31, 2026 | 48.46 Mn |
| Dec 31, 2025 | 58.63 Mn |
| Sep 30, 2025 | 55.90 Mn |
| Jun 30, 2025 | 55.74 Mn |
| Mar 31, 2025 | 53.03 Mn |
| Dec 31, 2024 | 53.12 Mn |
| Sep 30, 2024 | 52.91 Mn |
| Jun 30, 2024 | 49.92 Mn |
| Mar 31, 2024 | 70.10 Mn |
| Dec 31, 2023 | 160.43 Mn |
| Sep 30, 2023 | 106.57 Mn |
| Jun 30, 2023 | 93.26 Mn |
| Mar 31, 2023 | 100.18 Mn |
| Dec 31, 2022 | 96.85 Mn |
| Sep 30, 2022 | 125.87 Mn |
| Jun 30, 2022 | 104.16 Mn |
| Mar 31, 2022 | 141.04 Mn |
| Dec 31, 2021 | 112.92 Mn |
| Sep 30, 2021 | 115.29 Mn |